Human amniotic membrane (hAM) and human amniotic fluid (hAF) have been shown to reduce inflammation, have antimicrobial properties, and confer a low risk of immunogenicity. Indeed, human amniotic products have a broad immune mediating profile. These observations raise the question of whether or not there is something intrinsically protective in the fluid. Trial Registration : NCT04319731 March 23, 2020Įarly data in the COVID-19 pandemic suggested that vertical transmission from SARS CoV-2-infected women is uncommon and virus has not been detected in the amniotic fluid. Acknowledging some of the inherent limitations of this case series, these results inform and catalyze a larger scaled randomized prospective trial to further investigate hAF as a therapy for COVID-19. No hAF-related adverse events were noted. In this latter group, patients that had observed reductions in C-reactive protein were associated with improved clinical outcomes. The study design was altered by the IRB such that the last 6 patients received higher dose of intravenous hAF. Nine of the 10 patients survived to discharge, with one patient succumbing to the disease when enrolled on maximal ventilatory support and severe hypoxia. ResultsĪ 10-patient case series was IRB-approved to study the impact of hAF on hospitalized patients with documented COVID-19. Observing that many COVID-19 patients have a profound inflammatory response to the virus, we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19. Human amniotic products have a broad immune-mediating profile. Vertical transmission from SARS CoV-2-infected women is uncommon and coronavirus has not been detected in amniotic fluid.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |